Lantern Pharma
Open
$2.09
Prev. Close
$2.09
High
$2.09
Low
$2.08
Market Snapshot
$22.15M
-1.3
-1.93
24
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
emptyResult
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Recently from Cashu
Lantern Pharma Leverages AI to Transform Antibody-Drug Conjugate Development in Cancer Therapy
Revolutionizing Antibody-Drug Conjugate Development with AI Lantern Pharma Inc., an innovator in cancer therapies leveraging artificial intelligence (AI), is making substantial strides in the developm…
Lantern Pharma Leverages AI to Revolutionize Antibody-Drug Conjugate Development
Lantern Pharma Accelerates ADC Development with AI Innovations Lantern Pharma Inc., an artificial intelligence-driven biotech company, is revolutionizing the landscape of antibody-drug conjugates (ADC…
Lantern Pharma Transforms Antibody-Drug Conjugate Development Using AI Technology
Lantern Pharma Leverages AI to Revolutionize Antibody-Drug Conjugate Development Lantern Pharma Inc. is making significant strides in the field of cancer therapies through its innovative use of the RA…
Lantern Pharma's LP-184 Shows Promise in Glioblastoma Treatment with New Preclinical Data
Lantern Pharma Advances Glioblastoma Treatment with Promising Preclinical Data for LP-184 Lantern Pharma Inc., an innovative player in the oncology landscape, unveils exciting preclinical data and out…